Share Price and Basic Stock Data
Last Updated: February 3, 2026, 2:41 am
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Nectar Lifescience Ltd operates within the pharmaceuticals industry, focusing on the production and distribution of various medicinal products. As of the latest market data, the company’s share price stood at ₹13.9, with a market capitalization of ₹269 Cr. In terms of sales performance, the company reported revenues of ₹1,520 Cr for the fiscal year ending March 2023, which represented a decline from ₹1,665 Cr in March 2022. The trailing twelve months (TTM) revenue was reported at ₹897 Cr. Quarterly sales have shown fluctuations, with the highest quarterly revenue recorded at ₹452 Cr in December 2023, though this was followed by a decline to ₹441 Cr in March 2024. The company’s operational challenges are evident, as reflected in the inconsistent revenue trends, which could be attributed to competitive pressures and changing market dynamics in the pharmaceutical sector.
Profitability and Efficiency Metrics
Nectar Lifescience’s profitability metrics reveal significant challenges, with a reported net profit of -₹361 Cr as of March 2025, marking a stark decline from a profit of ₹25 Cr in March 2022. The operating profit margin (OPM) for the latest fiscal year stood at -2%, indicating that the company is struggling to generate profit from its operations. The interest coverage ratio (ICR) was recorded at -0.32x, suggesting that the company’s earnings are insufficient to cover its interest obligations, thereby raising concerns about its financial health. Additionally, the return on equity (ROE) and return on capital employed (ROCE) were reported at 11.2% and 5.36%, respectively. These figures highlight a lower efficiency in utilizing equity and capital compared to industry benchmarks, which typically range higher for established pharmaceutical firms.
Balance Sheet Strength and Financial Ratios
The balance sheet of Nectar Lifescience reveals a mixed picture of financial health. Total assets amounted to ₹2,047 Cr, while total liabilities were recorded at ₹2,191 Cr, resulting in a negative net worth situation. The company reported reserves of ₹934 Cr and borrowings of ₹582 Cr as of March 2025. The price-to-book value (P/BV) ratio stood at 0.53x, indicating that the stock is trading at a discount relative to its book value, which may signal undervaluation or concerns regarding future profitability. The current ratio was reported at 1.26, suggesting a relatively stable liquidity position. However, the increase in borrowings from ₹459 Cr in September 2025 indicates a growing reliance on debt, which may impact financial stability if not managed carefully.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Nectar Lifescience reflects a diverse investor base, with promoters holding 44.91% of the equity as of September 2025. Foreign institutional investors (FIIs) have a minimal stake of 0.62%, while domestic institutional investors (DIIs) hold 0.08%. Public shareholding constitutes 54.37%, showing a significant retail investor presence. The number of shareholders has increased to 76,470, indicating growing interest despite the company’s financial challenges. The decline in promoter holding from 55.80% in December 2022 to 44.91% raises questions about confidence levels among major stakeholders. The low institutional participation may hinder the company’s ability to attract larger investments, further complicating its recovery efforts.
Outlook, Risks, and Final Insight
The outlook for Nectar Lifescience remains uncertain amid operational struggles and declining profitability. Key risks include the negative net profit trend, high debt levels, and a low interest coverage ratio, which could impede growth and financial stability. The company’s reliance on fluctuating revenue streams poses additional challenges in maintaining operational efficiency. However, the presence of a large public shareholder base could provide some resilience, as retail investors often maintain longer-term perspectives. Should the company manage to stabilize its operations and restore profitability, there may be potential for recovery. Conversely, continued losses and high debt could lead to further financial distress, necessitating strategic restructuring or additional capital to ensure sustainable operations in this competitive landscape.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 122 Cr. | 97.0 | 193/84.3 | 27.0 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.21 Cr. | 1.68 | 4.29/1.68 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 3,473 Cr. | 319 | 479/192 | 71.9 | 24.3 | 0.21 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 32.9 Cr. | 44.3 | 82.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 73.2 Cr. | 50.0 | 50.0/17.0 | 174 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,464.08 Cr | 1,084.45 | 46.05 | 202.32 | 0.38% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 389 | 344 | 389 | 394 | 398 | 452 | 441 | 359 | 6 | 455 | 431 | 5 | 6 |
| Expenses | 396 | 343 | 371 | 359 | 371 | 410 | 393 | 319 | 6 | 410 | 585 | 6 | 6 |
| Operating Profit | -7 | 1 | 18 | 36 | 27 | 42 | 48 | 40 | -1 | 45 | -154 | -1 | -0 |
| OPM % | -2% | 0% | 5% | 9% | 7% | 9% | 11% | 11% | -10% | 10% | -36% | -16% | -6% |
| Other Income | 11 | 13 | 18 | 0 | 11 | 0 | 1 | 1 | 7 | 1 | 0 | -62 | -176 |
| Interest | 21 | 17 | 20 | 18 | 21 | 25 | 24 | 20 | 0 | 17 | 18 | 0 | 0 |
| Depreciation | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 0 | 16 | 16 | 1 | 0 |
| Profit before tax | -32 | -18 | 2 | 3 | 2 | 2 | 11 | 5 | 5 | 13 | -188 | -64 | -176 |
| Tax % | -31% | -47% | -145% | 41% | 38% | 36% | 95% | 40% | -2% | 38% | -31% | -1% | -0% |
| Net Profit | -22 | -9 | 4 | 2 | 1 | 2 | 1 | 3 | 6 | 8 | -130 | -63 | -176 |
| EPS in Rs | -1.00 | -0.41 | 0.16 | 0.08 | 0.05 | 0.07 | 0.03 | 0.13 | 0.25 | 0.35 | -5.80 | -2.82 | -7.85 |
Last Updated: December 29, 2025, 8:07 pm
Below is a detailed analysis of the quarterly data for Nectar Lifescience Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 6.00 Cr.. The value appears strong and on an upward trend. It has increased from 5.00 Cr. (Jun 2025) to 6.00 Cr., marking an increase of 1.00 Cr..
- For Expenses, as of Sep 2025, the value is 6.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 6.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 0.00 Cr.. The value appears strong and on an upward trend. It has increased from -1.00 Cr. (Jun 2025) to 0.00 Cr., marking an increase of 1.00 Cr..
- For OPM %, as of Sep 2025, the value is -6.00%. The value appears strong and on an upward trend. It has increased from -16.00% (Jun 2025) to -6.00%, marking an increase of 10.00%.
- For Other Income, as of Sep 2025, the value is -176.00 Cr.. The value appears to be declining and may need further review. It has decreased from -62.00 Cr. (Jun 2025) to -176.00 Cr., marking a decrease of 114.00 Cr..
- For Interest, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.00 Cr..
- For Depreciation, as of Sep 2025, the value is 0.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1.00 Cr. (Jun 2025) to 0.00 Cr., marking a decrease of 1.00 Cr..
- For Profit before tax, as of Sep 2025, the value is -176.00 Cr.. The value appears to be declining and may need further review. It has decreased from -64.00 Cr. (Jun 2025) to -176.00 Cr., marking a decrease of 112.00 Cr..
- For Tax %, as of Sep 2025, the value is 0.00%. The value appears to be increasing, which may not be favorable. It has increased from -1.00% (Jun 2025) to 0.00%, marking an increase of 1.00%.
- For Net Profit, as of Sep 2025, the value is -176.00 Cr.. The value appears to be declining and may need further review. It has decreased from -63.00 Cr. (Jun 2025) to -176.00 Cr., marking a decrease of 113.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is -7.85. The value appears to be declining and may need further review. It has decreased from -2.82 (Jun 2025) to -7.85, marking a decrease of 5.03.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:54 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,634 | 1,638 | 1,674 | 1,635 | 1,874 | 2,779 | 2,363 | 1,541 | 1,665 | 1,520 | 1,682 | 1,664 | 897 |
| Expenses | 1,345 | 1,371 | 1,436 | 1,411 | 1,638 | 2,514 | 2,143 | 1,432 | 1,507 | 1,467 | 1,530 | 1,694 | 1,007 |
| Operating Profit | 289 | 267 | 239 | 224 | 236 | 264 | 220 | 109 | 159 | 53 | 152 | -30 | -111 |
| OPM % | 18% | 16% | 14% | 14% | 13% | 10% | 9% | 7% | 10% | 3% | 9% | -2% | -12% |
| Other Income | 12 | 20 | 6 | 23 | 6 | 6 | 4 | -22 | 11 | 43 | 15 | 5 | -237 |
| Interest | 138 | 126 | 123 | 117 | 115 | 148 | 126 | 112 | 79 | 79 | 87 | 75 | 35 |
| Depreciation | 84 | 77 | 57 | 62 | 64 | 63 | 61 | 60 | 57 | 59 | 61 | 62 | 32 |
| Profit before tax | 78 | 85 | 64 | 67 | 63 | 59 | 37 | -85 | 34 | -42 | 18 | -162 | -415 |
| Tax % | 21% | 22% | 15% | 18% | 17% | 19% | 15% | -14% | 26% | -43% | 73% | -30% | |
| Net Profit | 62 | 66 | 54 | 55 | 52 | 48 | 32 | -73 | 25 | -24 | 5 | -114 | -361 |
| EPS in Rs | 2.77 | 2.95 | 2.42 | 2.47 | 2.33 | 2.12 | 1.42 | -3.27 | 1.12 | -1.08 | 0.22 | -5.07 | -16.12 |
| Dividend Payout % | 4% | 3% | 4% | 2% | 2% | 2% | 4% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 6.45% | -18.18% | 1.85% | -5.45% | -7.69% | -33.33% | -328.12% | 134.25% | -196.00% | 120.83% | -2380.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | -24.63% | 20.03% | -7.31% | -2.24% | -25.64% | -294.79% | 462.37% | -330.25% | 316.83% | -2500.83% |
Nectar Lifescience Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | -7% |
| 3 Years: | 0% |
| TTM: | -3% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -3025% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | -8% |
| 5 Years: | -7% |
| 3 Years: | -14% |
| 1 Year: | -69% |
| Return on Equity | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | -4% |
| 3 Years: | -6% |
| Last Year: | -11% |
Last Updated: September 5, 2025, 11:35 am
Balance Sheet
Last Updated: December 4, 2025, 1:42 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 |
| Reserves | 905 | 936 | 932 | 984 | 1,036 | 1,083 | 1,114 | 1,040 | 1,065 | 1,042 | 1,047 | 934 | 694 |
| Borrowings | 858 | 925 | 962 | 878 | 955 | 903 | 779 | 903 | 860 | 754 | 636 | 582 | 459 |
| Other Liabilities | 609 | 628 | 640 | 696 | 710 | 696 | 718 | 423 | 443 | 371 | 486 | 509 | 639 |
| Total Liabilities | 2,394 | 2,510 | 2,556 | 2,581 | 2,724 | 2,705 | 2,633 | 2,388 | 2,391 | 2,189 | 2,191 | 2,047 | 1,815 |
| Fixed Assets | 948 | 934 | 906 | 881 | 852 | 825 | 785 | 772 | 723 | 662 | 643 | 633 | 28 |
| CWIP | 122 | 91 | 99 | 102 | 100 | 100 | 115 | 99 | 85 | 78 | 66 | 57 | 0 |
| Investments | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 |
| Other Assets | 1,324 | 1,485 | 1,551 | 1,597 | 1,771 | 1,780 | 1,733 | 1,517 | 1,582 | 1,449 | 1,482 | 1,357 | 1,786 |
| Total Assets | 2,394 | 2,510 | 2,556 | 2,581 | 2,724 | 2,705 | 2,633 | 2,388 | 2,391 | 2,189 | 2,191 | 2,047 | 1,815 |
Below is a detailed analysis of the balance sheet data for Nectar Lifescience Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 22.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 22.00 Cr..
- For Reserves, as of Sep 2025, the value is 694.00 Cr.. The value appears to be declining and may need further review. It has decreased from 934.00 Cr. (Mar 2025) to 694.00 Cr., marking a decrease of 240.00 Cr..
- For Borrowings, as of Sep 2025, the value is 459.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 582.00 Cr. (Mar 2025) to 459.00 Cr., marking a decrease of 123.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 639.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 509.00 Cr. (Mar 2025) to 639.00 Cr., marking an increase of 130.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 1,815.00 Cr.. The value appears to be improving (decreasing). It has decreased from 2,047.00 Cr. (Mar 2025) to 1,815.00 Cr., marking a decrease of 232.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 28.00 Cr.. The value appears to be declining and may need further review. It has decreased from 633.00 Cr. (Mar 2025) to 28.00 Cr., marking a decrease of 605.00 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 57.00 Cr. (Mar 2025) to 0.00 Cr., marking a decrease of 57.00 Cr..
- For Investments, as of Sep 2025, the value is 1.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 1.00 Cr..
- For Other Assets, as of Sep 2025, the value is 1,786.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,357.00 Cr. (Mar 2025) to 1,786.00 Cr., marking an increase of 429.00 Cr..
- For Total Assets, as of Sep 2025, the value is 1,815.00 Cr.. The value appears to be declining and may need further review. It has decreased from 2,047.00 Cr. (Mar 2025) to 1,815.00 Cr., marking a decrease of 232.00 Cr..
Notably, the Reserves (694.00 Cr.) exceed the Borrowings (459.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -569.00 | -658.00 | -723.00 | -654.00 | -719.00 | -639.00 | -559.00 | -794.00 | -701.00 | -701.00 | -484.00 | -612.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 84 | 99 | 107 | 112 | 119 | 73 | 61 | 89 | 98 | 67 | 82 | 76 |
| Inventory Days | 240 | 253 | 260 | 270 | 226 | 151 | 192 | 185 | 197 | 212 | 215 | 184 |
| Days Payable | 139 | 146 | 154 | 167 | 142 | 80 | 104 | 108 | 112 | 100 | 127 | 117 |
| Cash Conversion Cycle | 185 | 207 | 213 | 215 | 203 | 145 | 150 | 166 | 182 | 179 | 170 | 143 |
| Working Capital Days | 23 | 40 | 41 | 45 | 67 | 46 | 53 | 6 | 73 | 77 | 63 | 43 |
| ROCE % | 12% | 11% | 10% | 10% | 9% | 10% | 8% | 3% | 5% | -0% | 6% | -5% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Basic EPS (Rs.) | -5.07 | 0.22 | -1.08 | 1.12 | -3.27 |
| Diluted EPS (Rs.) | -5.07 | 0.22 | -1.08 | 1.12 | -3.27 |
| Cash EPS (Rs.) | -2.29 | 2.93 | 1.56 | 3.66 | -0.58 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 42.63 | 47.68 | 47.47 | 48.51 | 47.36 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 42.63 | 47.68 | 47.47 | 48.51 | 47.36 |
| Revenue From Operations / Share (Rs.) | 74.47 | 75.10 | 67.94 | 74.42 | 68.82 |
| PBDIT / Share (Rs.) | -1.10 | 7.41 | 4.29 | 7.57 | 5.03 |
| PBIT / Share (Rs.) | -3.88 | 4.70 | 1.65 | 5.03 | 2.34 |
| PBT / Share (Rs.) | -7.20 | 0.81 | -1.89 | 1.52 | -3.78 |
| Net Profit / Share (Rs.) | -5.07 | 0.22 | -1.08 | 1.12 | -3.27 |
| NP After MI And SOA / Share (Rs.) | -5.07 | 0.22 | -1.08 | 1.12 | -3.27 |
| PBDIT Margin (%) | -1.47 | 9.86 | 6.31 | 10.17 | 7.31 |
| PBIT Margin (%) | -5.20 | 6.25 | 2.43 | 6.76 | 3.40 |
| PBT Margin (%) | -9.67 | 1.08 | -2.78 | 2.04 | -5.49 |
| Net Profit Margin (%) | -6.80 | 0.29 | -1.58 | 1.50 | -4.74 |
| NP After MI And SOA Margin (%) | -6.80 | 0.29 | -1.58 | 1.50 | -4.74 |
| Return on Networth / Equity (%) | -11.88 | 0.46 | -2.27 | 2.30 | -6.89 |
| Return on Capital Employeed (%) | -8.47 | 8.65 | 2.85 | 8.13 | 4.09 |
| Return On Assets (%) | -5.55 | 0.22 | -1.10 | 1.04 | -2.96 |
| Long Term Debt / Equity (X) | 0.06 | 0.13 | 0.21 | 0.26 | 0.12 |
| Total Debt / Equity (X) | 0.60 | 0.59 | 0.70 | 0.79 | 0.79 |
| Asset Turnover Ratio (%) | 0.78 | 0.76 | 0.66 | 0.68 | 0.60 |
| Current Ratio (X) | 1.26 | 1.50 | 1.59 | 1.56 | 1.04 |
| Quick Ratio (X) | 0.53 | 0.59 | 0.62 | 0.69 | 0.54 |
| Inventory Turnover Ratio (X) | 2.05 | 1.42 | 1.39 | 1.65 | 1.13 |
| Dividend Payout Ratio (NP) (%) | 0.00 | 0.00 | 0.00 | 0.00 | -1.53 |
| Dividend Payout Ratio (CP) (%) | 0.00 | 0.00 | 0.00 | 0.00 | -8.61 |
| Earning Retention Ratio (%) | 0.00 | 0.00 | 0.00 | 0.00 | 101.53 |
| Cash Earning Retention Ratio (%) | 0.00 | 0.00 | 0.00 | 0.00 | 108.61 |
| Interest Coverage Ratio (X) | -0.32 | 1.91 | 1.21 | 2.16 | 1.01 |
| Interest Coverage Ratio (Post Tax) (X) | -0.52 | 1.06 | 0.69 | 1.32 | 0.57 |
| Enterprise Value (Cr.) | 1078.15 | 1290.98 | 1091.93 | 1381.46 | 1231.83 |
| EV / Net Operating Revenue (X) | 0.64 | 0.76 | 0.71 | 0.82 | 0.79 |
| EV / EBITDA (X) | -43.89 | 7.77 | 11.35 | 8.13 | 10.92 |
| MarketCap / Net Operating Revenue (X) | 0.30 | 0.40 | 0.23 | 0.32 | 0.27 |
| Retention Ratios (%) | 0.00 | 0.00 | 0.00 | 0.00 | 101.53 |
| Price / BV (X) | 0.53 | 0.63 | 0.33 | 0.49 | 0.39 |
| Price / Net Operating Revenue (X) | 0.30 | 0.40 | 0.23 | 0.32 | 0.27 |
| EarningsYield | -0.22 | 0.01 | -0.06 | 0.04 | -0.17 |
After reviewing the key financial ratios for Nectar Lifescience Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -5.07. This value is below the healthy minimum of 5. It has decreased from 0.22 (Mar 24) to -5.07, marking a decrease of 5.29.
- For Diluted EPS (Rs.), as of Mar 25, the value is -5.07. This value is below the healthy minimum of 5. It has decreased from 0.22 (Mar 24) to -5.07, marking a decrease of 5.29.
- For Cash EPS (Rs.), as of Mar 25, the value is -2.29. This value is below the healthy minimum of 3. It has decreased from 2.93 (Mar 24) to -2.29, marking a decrease of 5.22.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 42.63. It has decreased from 47.68 (Mar 24) to 42.63, marking a decrease of 5.05.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 42.63. It has decreased from 47.68 (Mar 24) to 42.63, marking a decrease of 5.05.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 74.47. It has decreased from 75.10 (Mar 24) to 74.47, marking a decrease of 0.63.
- For PBDIT / Share (Rs.), as of Mar 25, the value is -1.10. This value is below the healthy minimum of 2. It has decreased from 7.41 (Mar 24) to -1.10, marking a decrease of 8.51.
- For PBIT / Share (Rs.), as of Mar 25, the value is -3.88. This value is below the healthy minimum of 0. It has decreased from 4.70 (Mar 24) to -3.88, marking a decrease of 8.58.
- For PBT / Share (Rs.), as of Mar 25, the value is -7.20. This value is below the healthy minimum of 0. It has decreased from 0.81 (Mar 24) to -7.20, marking a decrease of 8.01.
- For Net Profit / Share (Rs.), as of Mar 25, the value is -5.07. This value is below the healthy minimum of 2. It has decreased from 0.22 (Mar 24) to -5.07, marking a decrease of 5.29.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is -5.07. This value is below the healthy minimum of 2. It has decreased from 0.22 (Mar 24) to -5.07, marking a decrease of 5.29.
- For PBDIT Margin (%), as of Mar 25, the value is -1.47. This value is below the healthy minimum of 10. It has decreased from 9.86 (Mar 24) to -1.47, marking a decrease of 11.33.
- For PBIT Margin (%), as of Mar 25, the value is -5.20. This value is below the healthy minimum of 10. It has decreased from 6.25 (Mar 24) to -5.20, marking a decrease of 11.45.
- For PBT Margin (%), as of Mar 25, the value is -9.67. This value is below the healthy minimum of 10. It has decreased from 1.08 (Mar 24) to -9.67, marking a decrease of 10.75.
- For Net Profit Margin (%), as of Mar 25, the value is -6.80. This value is below the healthy minimum of 5. It has decreased from 0.29 (Mar 24) to -6.80, marking a decrease of 7.09.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is -6.80. This value is below the healthy minimum of 8. It has decreased from 0.29 (Mar 24) to -6.80, marking a decrease of 7.09.
- For Return on Networth / Equity (%), as of Mar 25, the value is -11.88. This value is below the healthy minimum of 15. It has decreased from 0.46 (Mar 24) to -11.88, marking a decrease of 12.34.
- For Return on Capital Employeed (%), as of Mar 25, the value is -8.47. This value is below the healthy minimum of 10. It has decreased from 8.65 (Mar 24) to -8.47, marking a decrease of 17.12.
- For Return On Assets (%), as of Mar 25, the value is -5.55. This value is below the healthy minimum of 5. It has decreased from 0.22 (Mar 24) to -5.55, marking a decrease of 5.77.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.06. This value is below the healthy minimum of 0.2. It has decreased from 0.13 (Mar 24) to 0.06, marking a decrease of 0.07.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.60. This value is within the healthy range. It has increased from 0.59 (Mar 24) to 0.60, marking an increase of 0.01.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.78. It has increased from 0.76 (Mar 24) to 0.78, marking an increase of 0.02.
- For Current Ratio (X), as of Mar 25, the value is 1.26. This value is below the healthy minimum of 1.5. It has decreased from 1.50 (Mar 24) to 1.26, marking a decrease of 0.24.
- For Quick Ratio (X), as of Mar 25, the value is 0.53. This value is below the healthy minimum of 1. It has decreased from 0.59 (Mar 24) to 0.53, marking a decrease of 0.06.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 2.05. This value is below the healthy minimum of 4. It has increased from 1.42 (Mar 24) to 2.05, marking an increase of 0.63.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Interest Coverage Ratio (X), as of Mar 25, the value is -0.32. This value is below the healthy minimum of 3. It has decreased from 1.91 (Mar 24) to -0.32, marking a decrease of 2.23.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is -0.52. This value is below the healthy minimum of 3. It has decreased from 1.06 (Mar 24) to -0.52, marking a decrease of 1.58.
- For Enterprise Value (Cr.), as of Mar 25, the value is 1,078.15. It has decreased from 1,290.98 (Mar 24) to 1,078.15, marking a decrease of 212.83.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.64. This value is below the healthy minimum of 1. It has decreased from 0.76 (Mar 24) to 0.64, marking a decrease of 0.12.
- For EV / EBITDA (X), as of Mar 25, the value is -43.89. This value is below the healthy minimum of 5. It has decreased from 7.77 (Mar 24) to -43.89, marking a decrease of 51.66.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.30. This value is below the healthy minimum of 1. It has decreased from 0.40 (Mar 24) to 0.30, marking a decrease of 0.10.
- For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Price / BV (X), as of Mar 25, the value is 0.53. This value is below the healthy minimum of 1. It has decreased from 0.63 (Mar 24) to 0.53, marking a decrease of 0.10.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.30. This value is below the healthy minimum of 1. It has decreased from 0.40 (Mar 24) to 0.30, marking a decrease of 0.10.
- For EarningsYield, as of Mar 25, the value is -0.22. This value is below the healthy minimum of 5. It has decreased from 0.01 (Mar 24) to -0.22, marking a decrease of 0.23.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Nectar Lifescience Ltd:
- Net Profit Margin: -6.8%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: -8.47% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -11.88% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): -0.52
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.53
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 46.05)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.6
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -6.8%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Village Saidpura, Tehsil Derabassi, Mohali Punjab 140507 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Sanjiv Goyal | Chairman & Managing Director |
| Dr. Surulichamy Senethilkumar | Director - R & D |
| Dr. Indu Pal Kaur | Independent Director |
| Ms. Meena Verma | Nominee Director |
| Dr. Rupinder Tewari | Independent Director |
| Dr. Kuldip Kumar Bhasin | Independent Director |
FAQ
What is the intrinsic value of Nectar Lifescience Ltd?
Nectar Lifescience Ltd's intrinsic value (as of 03 February 2026) is ₹24.54 which is 76.55% higher the current market price of ₹13.90, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's ₹269 Cr. market cap, FY2025-2026 high/low of ₹38.9/13.0, reserves of ₹694 Cr, and liabilities of ₹1,815 Cr.
What is the Market Cap of Nectar Lifescience Ltd?
The Market Cap of Nectar Lifescience Ltd is 269 Cr..
What is the current Stock Price of Nectar Lifescience Ltd as on 03 February 2026?
The current stock price of Nectar Lifescience Ltd as on 03 February 2026 is ₹13.9.
What is the High / Low of Nectar Lifescience Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Nectar Lifescience Ltd stocks is ₹38.9/13.0.
What is the Stock P/E of Nectar Lifescience Ltd?
The Stock P/E of Nectar Lifescience Ltd is .
What is the Book Value of Nectar Lifescience Ltd?
The Book Value of Nectar Lifescience Ltd is 32.0.
What is the Dividend Yield of Nectar Lifescience Ltd?
The Dividend Yield of Nectar Lifescience Ltd is 0.00 %.
What is the ROCE of Nectar Lifescience Ltd?
The ROCE of Nectar Lifescience Ltd is 5.36 %.
What is the ROE of Nectar Lifescience Ltd?
The ROE of Nectar Lifescience Ltd is 11.2 %.
What is the Face Value of Nectar Lifescience Ltd?
The Face Value of Nectar Lifescience Ltd is 1.00.